4th booster-dose SARS-CoV-2 heterologous and homologous vaccination in rheumatological patients.

Objective: to evaluate the immune response to the SARS-CoV-2 vaccines in adults with immune-mediated rheumatic diseases (IMRDs) in comparison to healthy individuals, observed 1-20 weeks following the fourth vaccine dose. Additionally, to evaluate the impact of immunosuppressive therapies, vaccination schedules, the time interval between vaccination and sample collection on the vaccine's immune response. Methods: We designed a longitudinal observational study conducted at the rheumatology department of Hospital de Copiapó. Neutralizing antibodies (Nabs) titers against the Wuhan and Omicron variant were analyzed between 1-20 weeks after administration of the fourth dose of the SARS-CoV-2 vaccine to 341 participants (218 IMRD patients and 123 healthy controls). 218 IMRD patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), systemic vasculitis (VS) and systemic scleroderma (SS) were analyzed. Results: Performing a comparison between the variants, Wuhan vs Omicron, we noticed that there were significant differences (p<0.05) in the level of the ID50, both for healthy controls and for patients with IMRDs. The humoral response of patients with IMRDs is significantly lower compared to healthy controls for the Omicron variant of SARS-CoV-2 (p = 0.0015). The humoral response of patients with IMRDs decreases significantly when the time interval between vaccination and sample collection is greater than 35 days. This difference was observed in the response, both for the Wuhan variant and for the Omicron variant. Conclusion: The IMRDs patients, the humoral response variation in the SARS-CoV-2 vaccine depends on doses and type of vaccine administered, the humoral response times and the treatment that these patients are receiving.

Immune responses during COVID-19 breakthrough cases in vaccinated children and adolescents.

Background: Vaccine effectiveness against SARS-CoV-2 infection has been somewhat limited due to the widespread dissemination of the Omicron variant, its subvariants, and the immune response dynamics of the naturally infected with the virus. Methods: Twelve subjects between 3-17 years old (yo), vaccinated with two doses of CoronaVac®, were followed and diagnosed as breakthrough cases starting 14 days after receiving the second dose. Total IgGs against different SARS-CoV-2 proteins and the neutralizing capacity of these antibodies after infection were measured in plasma. The activation of CD4+ and CD8+ T cells was evaluated in peripheral blood mononuclear cells stimulated with peptides derived from the proteins from the wild-type (WT) virus and Omicron subvariants by flow cytometry, as well as different cytokines secretion by a Multiplex assay. Results: 2 to 8 weeks post-infection, compared to 4 weeks after 2nd dose of vaccine, there was a 146.5-fold increase in neutralizing antibody titers against Omicron and a 38.7-fold increase against WT SARS-CoV-2. Subjects showed an increase in total IgG levels against the S1, N, M, and NSP8 proteins of the WT virus. Activated CD4+ T cells showed a significant increase in response to the BA.2 subvariant (p<0.001). Finally, the secretion of IL-2 and IFN-γ cytokines showed a discreet decrease trend after infection in some subjects. Conclusion: SARS-CoV-2 infection in the pediatric population vaccinated with an inactivated SARS-CoV-2 vaccine produced an increase in neutralizing antibodies against Omicron and increased specific IgG antibodies for different SARS-CoV-2 proteins. CD4+ T cell activation was also increased, suggesting a conserved cellular response against the Omicron subvariants, whereas Th1-type cytokine secretion tended to decrease. Clinical Trial Registration: clinicaltrials.gov #NCT04992260.

Identificación molecular de Ehrlichia canis en un canino de la ciudad de Arica, Chile / Molecular identification of Ehrlichia canis in a dog from Arica, Chile

We report a molecular confirmed case of canine ehrlichiosis caused by Ehrlichia canis. A 10-year old female crossbred Siberian from the city of Arica, which was infested by ticks, presented hemorrhagic manifestations (hematomas and snout bleeding) and prostration. Blood cell count revealed thrombocytopenia (30,000 platelets/ mm³). Immunochromatographic rapid testing for E. canis IgG was positive. Amplification and sequencing of a fragment of the 16S rRNA gen from a blood sample showed 100% homology with E. canis from Perú. This is the first report of E. canis in Chile, an agent with known zoonotic potential.

Se reporta un caso clínico de ehrlichiosis causada por Ehrlichia canis en un perro de la ciudad fronteriza de Arica, confirmado por técnicas moleculares. Un canino hembra de 10 años, mestizo siberiano, parasitado con garrapatas presentó un cuadro de hematomas, sangrado bucal profuso y marcado compromiso del estado general. En sus exámenes generales destacaba trombocitopenia (30.000 plaquetas/mm³); un test rápido inmunocromatográfico para Ehrlichia canis fue positivo. La amplificación y secuenciación de un fragmento del gen 16S ARNr a partir de muestra de sangre mostró 100% de homología con E. canis de Perú. Se trata del primer reporte de la presencia de E. canis en Chile, agente de reconocido poder zoonótico.

Identificación morfológica y molecular de filarías caninas en una comuna semi-rural de la Región Metropolitana, Chile / Morphological and molecular identification of canine filariae in a semi-rural district of the Metropolitan Region in Chile

Introduction: To date, there has been no definitive confirmation of the presence of zoonotic dirofilariasis in dogs in Chile. Objectives: To study the presence of dirofilarias in blood samples from dogs collected in a semi-rural district near Santiago and to compare their frequency in dogs with and without dermatological manifestations. Methods: We examined 100 blood samples for dog filariae infections using microscopic methods (modified Knott technique). 50 dogs presented dermatological symptoms or signs compatible with filarial infections and 50 were asymptomatic. ITS-2 and 12s rDNA gene amplification by PCR and sequencing were performed in samples microscopically positive for microfilariae. Results. We observed microfilariae in 22 dogs (22%). Of these, 16/50 (32%) were symptomatic and 6/50 (12%) were asymptomatic (p = 0.02). Morphologically, the majority of micro-filariae were similar to Dirofilaria repens, although many had a bigger size than previously described. Nucleotide sequencing of the amplified genes showed no more than 95% homology with the D. repens sequences available for comparison. D. reconditum and D. dracunculoides infections were also identified. Conclusions: These features might indicate the presence of new species of Dirofilaria or a D. repens close related variant in Chile.

Introducción: A la fecha no hay datos concluyentes en Chile respecto a la presencia de dirofilariasis zoonótica en perros. Objetivos: Identificar la presencia de dirofilarias en sangre de perros de una comuna semi-rural cercana a Santiago y comparar su frecuencia en animales con y sin manifestaciones dermatológicas. Materialy Métodos. Se examinó un frotis sanguíneo de 100 perros en busca de microfilarias mediante observación microscópica (técnica de Knott modificada). Cincuenta perros presentaban síntomas o signos dermatológicos que se han asociado a esta parasitosis y 50 eran asintomáticos. Se amplificaron los genes ITS-2 y 12s ADNr de filarías en las muestras con microfilarias al frotis, secuenciando los fragmentos amplificados. Resultados: Se observaron microfilarias en 22 perros (22%), 16/50 (32%) sintomáticos y 6/50 (12%) asintomáticos (p = 0,02). Morfológicamente, la mayoría de las microfilarias observadas fueron similares a D. repens; sin embargo, una gran proporción mostró un tamaño mayor al descrito para esta especie. Las secuencias nucleotídicas de los genes amplificados mostraron una homología no mayor al 95% con las secuencias de D. repens disponibles para comparación. Se identificaron además dos especies poco patógenas, D. reconditum por morfología y secuenciación genética y D. dracunculoides por morfología. Conclusiones: Los resultados indican la existencia de una nueva especie de Dirofilaria cercanamente relacionada a D. repens o de una variante de esta especie.

Bocavirus humano en Chile: características clínicas y epidemiológicas en niños con infecciones respiratorias / Human bocavirus in Chile: clinical characteristics and epidemiological profile in children with acute respiratory tract infections

Background: Human bocavirus (HBoV) is a newly discovered parvovirus found in children with acute respiratory tract infections (ARTI). Objectives: To describe the epidemiological and clinical profile of children < 5 years old consulting for ARTI, comparing cases of HBoV monoinfection and coinfection with other known respiratory viruses. Furthermore, we aimed to estimate the prevalence of viral shedding in asymptomatic children and perform phylogenetic analysis. Patients and Methods: We investigated the presence of HBoV in nasopharyngeal secretions from children consulting for AlRTI and among asymptomatic controls, between 2007 and 2008, by polymerase chain reaction. Results: HBoV was detected in 79 (21.8 percent) of 362 nasopharyngeal swabs obtained from children with ARTI. In 60/79 (76 percent), coinfection with other respiratory viruses was confirmed. Most common symptoms were cough, fever and rhinorrhea. Children infected only with HBoV showed significantly lower frequencies of respiratory distress, oxygen requirements and hospital admission than those with coinfection. HBoV was detected in 6/16 (37.5 percent) samples from asymptomatic children. The phylogenetic analysis of viruses from Chilean patients revealed that circulating HBoV was closely related to original strains. Conclusions: HBoV was found either in symptomatic and asymptomatic children. The severity of the disease was greater when HBoV was associated to other respiratory viruses.

Introducción: Bocavirus humano (HBoV) es un nuevo parvovirus encontrado en niños con infecciones respiratorias agudas (IRA). Objetivos: Describir la epidemiología y perfil clínico en niños < 5 años con IRA, comparando aquellos con HBoV como único agente identificado, con los que tenían co-infección con otro virus respiratorio. Además se evaluó su prevalencia en niños asintomáticos, y se realizó análisis filogenético. Materiales y Métodos: Se investigó la presencia de HBoV, por medio de reacción de polimerasa en cadena, en muestras de secreción nasofaríngea obtenida en niños con IRA y en controles asintomáticos, entre 2007 y 2008. Resultados: Se detectó HBoV en 79 (21,8 por ciento) de 362 muestras obtenidas en pacientes con IRA. En 60/79 (76 por ciento), se demostró co-infección. Los síntomas más frecuentes fueron tos, fiebre y rinorrea. Los pacientes con HBoV como único agente identificado mostraron frecuencias significativamente menores de dificultad respiratoria, requerimiento de oxígeno y hospitalización, comparado con los co-infectados. HBoV se detectó en 6/16 (37,5 por ciento) muestras de niños asintomáticos. El análisis filogenético de las cepas chilenas demuestra estrecha relación con las cepas originales. Conclusiones: HBoV está presente en niños chilenos con IRA y asintomáticos. La gravedad de la enfermedad fue mayor en el grupo con co-infección.